Protherics PLC announces Director/PDMR Shareholding - 1

Cheshire, UK -- (MARKET WIRE) -- December 18, 2006 --

                                 Protherics PLC

                       Notification of Directors' Interests


London, UK; Brentwood, TN; 18 December 2006 - Protherics PLC (the "Company"),
the international biopharmaceutical company focused on critical care and cancer,
announces that, on 15 December 2006, options over 2p ordinary shares in the
Company were granted to the following directors under the terms of the
Protherics PLC Long Term Incentive Plan:


Name                               Number of Options
                                   Granted

Andrew J Heath                     215,304
Barry M Riley                      119,322
James C Christie                   118,644


The options are exercisable between the third and tenth anniversary of the date
of grant at a price of 2p per share, subject to the achievement of performance
conditions.

Following the above grant of options, the above directors hold options over the
following number of shares:


Andrew J Heath                     3,621,900
Barry M Riley                      1,456,227
James C Christie                   1,253,698



The current issued ordinary share capital of the Company is 261,489,793 shares.


                                   |  Ends  |


For further information please contact:


Protherics
Nick Staples, Director of Corporate Affairs               +44 (0) 7919  480510
Julie Vickers, Company Secretary                          +44 (0)1928 518010

Financial Dynamics - press enquiries
London: Ben Atwell, David Yates                           +44 (0) 20 7831 3113
New York: John Capodanno, Jonathan Birt                   +1 212 850 5600


Or visit  www.protherics.com





                      This information is provided by RNS
            The company news service from the London Stock Exchange